Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

239
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
239
Pneumothorax-II01:27

Pneumothorax-II

153
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
153
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

332
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
332
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

275
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
275
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

244
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
244

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities.

ERJ open research·2026
Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026
Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025

相关实验视频

Updated: Jul 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

纤维化肺部沙尔科毒症 纤维化肺部沙尔科毒症

Hilario Nunes1, Pierre-Yves Brillet2, Jean-François Bernaudin3

  • 1AP-HP, Pulmonology Department, Avicenne Hospital, Bobigny, 93009, France; INSERM UMR 1272, Sorbonne Paris-Nord University, Bobigny, 93009, France.

Clinics in chest medicine
|January 20, 2024
PubMed
概括

纤维性肺癌样症 (fPS) 显著影响患者的健康,结果因纤维化程度和并发症而异. 了解fPS进展对于有效的管理和治疗策略至关重要.

关键词:
纤维化 纤维化 纤维化这些都是小粒瘤.疾病发病率 疾病发病率死亡率 死亡率 死亡率一个进步的进步.

更多相关视频

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

446

相关实验视频

Last Updated: Jul 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

446

科学领域:

  • 肺部医学 肺部医学
  • 类风湿病学 类风湿病学
  • 免疫学 免疫学 免疫学

背景情况:

  • 纤维性肺性沙尔科毒症 (fPS) 影响了大约20%的沙尔科毒症患者.
  • fPS与严重的发病率和死亡率有关.
  • 在fPS的预后是高度可变的,受纤维化程度,功能障碍和肺高血压的影响.

研究的目的:

  • 为了调查纤维化肺癌沙科毒症的自然史.
  • 为了确定渐进的,自我维持的纤维化风险因素.
  • 评估目前fPS的管理挑战和治疗选择.

主要方法:

  • 审查有关纤维化肺癌沙科毒症的现有文献.
  • 分析患者数据以评估影响预后的因素.
  • 对抗炎症,康复,抗纤维素和移植策略的治疗结果的评估.

主要成果:

  • 预后取决于纤维化程度,功能障碍和肺高血压.
  • 急性恶化和感染是影响结果的重大并发症.
  • 自然史,特别是渐进性纤维化风险,仍然在很大程度上是未知的.

结论:

  • fPS的管理是复杂的,需要量身定制的方法.
  • 治疗可能包括抗炎药物,康复,抗纤维素剂,或肺移植在某些情况下.
  • 需要进一步的研究来了解fPS的自然历史,并优化治疗干预措施.